The landscape of somatic copy-number alteration across human cancers R Beroukhim, CH Mermel, D Porter, G Wei, S Raychaudhuri, J Donovan, ... Nature 463 (7283), 899-905, 2010 | 4393 | 2010 |
An inhibitor of Bcl-2 family proteins induces regression of solid tumours T Oltersdorf, SW Elmore, AR Shoemaker, RC Armstrong, DJ Augeri, ... Nature 435 (7042), 677-681, 2005 | 4118 | 2005 |
Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics A Letai, MC Bassik, LD Walensky, MD Sorcinelli, S Weiler, SJ Korsmeyer Cancer cell 2 (3), 183-192, 2002 | 2155 | 2002 |
Azacitidine and venetoclax in previously untreated acute myeloid leukemia CD DiNardo, BA Jonas, V Pullarkat, MJ Thirman, JS Garcia, AH Wei, ... New England Journal of Medicine 383 (7), 617-629, 2020 | 2064 | 2020 |
Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins R Singh, A Letai, K Sarosiek Nature reviews Molecular cell biology 20 (3), 175-193, 2019 | 1762 | 2019 |
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia CD DiNardo, K Pratz, V Pullarkat, BA Jonas, M Arellano, PS Becker, ... Blood, The Journal of the American Society of Hematology 133 (1), 7-17, 2019 | 1745 | 2019 |
Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members M Certo, VDG Moore, M Nishino, G Wei, S Korsmeyer, SA Armstrong, ... Cancer cell 9 (5), 351-365, 2006 | 1565 | 2006 |
Control of mitochondrial apoptosis by the Bcl-2 family JK Brunelle, A Letai Journal of cell science 122 (4), 437-441, 2009 | 1146 | 2009 |
Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia M Konopleva, DA Pollyea, J Potluri, B Chyla, L Hogdal, T Busman, ... Cancer discovery 6 (10), 1106-1117, 2016 | 1069 | 2016 |
Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1 JT Opferman, A Letai, C Beard, MD Sorcinelli, CC Ong, SJ Korsmeyer Nature 426 (6967), 671-676, 2003 | 1031 | 2003 |
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib D Chauhan, L Catley, G Li, K Podar, T Hideshima, M Velankar, ... Cancer cell 8 (5), 407-419, 2005 | 847 | 2005 |
Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737 VDG Moore, JR Brown, M Certo, TM Love, CD Novina, A Letai The Journal of clinical investigation 117 (1), 112-121, 2007 | 755 | 2007 |
Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia R Pan, LJ Hogdal, JM Benito, D Bucci, L Han, G Borthakur, J Cortes, ... Cancer discovery 4 (3), 362-375, 2014 | 746 | 2014 |
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label … CD DiNardo, KW Pratz, A Letai, BA Jonas, AH Wei, M Thirman, ... The lancet oncology 19 (2), 216-228, 2018 | 739 | 2018 |
Diagnosing and exploiting cancer's addiction to blocks in apoptosis AG Letai Nature Reviews Cancer 8 (2), 121-132, 2008 | 721 | 2008 |
Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy TN Chonghaile, KA Sarosiek, TT Vo, JA Ryan, A Tammareddi, ... Science 334 (6059), 1129-1133, 2011 | 650 | 2011 |
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer S Shu, CY Lin, HH He, RM Witwicki, DP Tabassum, JM Roberts, ... Nature 529 (7586), 413-417, 2016 | 622 | 2016 |
BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents J Deng, N Carlson, K Takeyama, P Dal Cin, M Shipp, A Letai Cancer cell 12 (2), 171-185, 2007 | 609 | 2007 |
Precision medicine for cancer with next-generation functional diagnostics AA Friedman, A Letai, DE Fisher, KT Flaherty Nature Reviews Cancer 15 (12), 747-756, 2015 | 597 | 2015 |
Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages JL Guerriero, A Sotayo, HE Ponichtera, JA Castrillon, AL Pourzia, ... Nature 543 (7645), 428-432, 2017 | 519 | 2017 |